- Home
- KF vs GNLX Comparison
KF vs GNLX Comparison
Compare KF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- GNLX
- Stock Information
- Founded
- KF 1984
- GNLX 2001
- Country
- KF United States
- GNLX United States
- Employees
- KF N/A
- GNLX N/A
- Industry
- KF Investment Managers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- GNLX Health Care
- Exchange
- KF Nasdaq
- GNLX Nasdaq
- Market Cap
- KF 113.5M
- GNLX 103.6M
- IPO Year
- KF N/A
- GNLX 2023
- Fundamental
- Price
- KF $19.77
- GNLX $2.36
- Analyst Decision
- KF
- GNLX Strong Buy
- Analyst Count
- KF 0
- GNLX 4
- Target Price
- KF N/A
- GNLX $18.25
- AVG Volume (30 Days)
- KF 18.4K
- GNLX 169.7K
- Earning Date
- KF 01-01-0001
- GNLX 11-14-2024
- Dividend Yield
- KF N/A
- GNLX N/A
- EPS Growth
- KF N/A
- GNLX N/A
- EPS
- KF N/A
- GNLX N/A
- Revenue
- KF N/A
- GNLX $8,000.00
- Revenue This Year
- KF N/A
- GNLX N/A
- Revenue Next Year
- KF N/A
- GNLX N/A
- P/E Ratio
- KF N/A
- GNLX N/A
- Revenue Growth
- KF N/A
- GNLX N/A
- 52 Week Low
- KF $18.30
- GNLX $1.60
- 52 Week High
- KF $25.56
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- KF 23.90
- GNLX 37.36
- Support Level
- KF $19.71
- GNLX $2.86
- Resistance Level
- KF $21.58
- GNLX $3.07
- Average True Range (ATR)
- KF 0.33
- GNLX 0.31
- MACD
- KF -0.15
- GNLX -0.07
- Stochastic Oscillator
- KF 2.40
- GNLX 2.56
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.